Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|October 13, 2015
Bohle Coating – Bohle Film Coater BFC
The BFC is the high-end version of the Bohle coater designed specifically for high speed, problem-free coating, providing unparalleled tablet uniformity and efficiencies. A high containment execution is also available.
Advertisement
Bohle coaters guarantee excellent product processing with exceptionally high profitability. The flat tablet bed in long drum geometry, as well as the continuous adjustment of the inclination angle ensures optimal movement of the cores. The integrated mixing spirals in the drum enable continuous product movement. There is no tablet twinning, therefore minor losses in solids and coatings.
Innovative concepts for processes as well as for cleaning improve the coater functionality and deliver outstanding results.
The type of air system reveals significant process-related advantages. Danger of spray drying of suspension no longer exists. This reduces spray losses and improves the structure of the coating. Tablets are handled more carefully thanks to the pan geometry and the mixing and conveyor elements. Through change of direction of pan rotation, tablets can be discharged completely and without containments.
The Bohle film coater BFC is the high-end version of the Bohle coater series designed specifically for high speed, problem-free coating, providing unparalleled tablet uniformity and efficiencies. A high containment execution is also available.
Marketing Manager
Tobias Borgers
+49 2524 – 9323 0
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement